|
Mefloquine Hydrochloride Tablets
Composition:
Mefloquine
Hydrochloride equivalent to
Mefloquine........................................................................250
mg
Indications :
Mexoquine is
for use as a second line treatment in chloroquine resistant
malaria, severe malaria due to P. falciparum and P. vivax
including cerebral malaria. Not to be used as a first line
treatment for malaria.
Description:
Mefloquine is an antimalarial
agent that acts as a blood schizonticide. It is effective
against all species of malaria (P. falciparum, P. vivax, P.
malariae and P. ovale). Its exact mechanism of action is not
known. Mefloquine is active against the erythrocytic stages
of Plasmodium species. However, the drug has no effect
against the exoerythrocytic (hepatic) stages of the parasite
and mature gametocytes. Mefloquine is effective against
malaria parasites resistant to chloroquine and
other 4-aminoquinoline
derivatives, proguanil, pyrimethamine and
pyrimethamine-sulphonamide combinations.
Similar to chloroquine and
quinine, mefloquine appears to interfere with the parasite's
ability to metabolize and utilise erythrocyte hemoglobin.
The antimalarial activity of mefloquine may depend on the
ability of the drug to form hydrogen bonds with cellular
constituents. Mefloquine binds to high-density lipoproteins
in serum, specifically polypeptide apo A and is delivered to
the erythrocytes where it interacts with a specific
erythrocyte membrane protein, stromatin and is then
transferred to the intracellular parasite by a pathway used
for exogenous phospholipids. Mefloquine may exert its
antimalarial action by disrupting the membrane trafficking
events involved in the uptake of phospholipids.
Cross resistance between
mefloquine and halofantrine and cross-resistance between
mefloquine and quinine have been observed in some regions.
In vitro and in vivo studies
with mefloquine showed no haemolysis associated with
glucose-6-phosphate dehydrogenase deficiency.
CONTRA-INDICATIONS:
Use of mefloquine is
contraindicated in patients with a known hypersensitivity to
mefloquine
 or
related compounds (eg, quinine and quinidine). Mefloquine
should not be prescribed for prophylaxis in patients with
active depression, a recent history of depression,
generalized anxiety disorder, psychosis, or schizophrenia or
other major psychiatric disorders, or with a history of
convulsions. The use of mefloquine is contraindicated in
persons who have received treatment with mefloquine in the
previous 4 weeks.
WARNINGS:
Patients with acute P. vivax
malaria, treated with mefloquine, are at high risk of
relapse because mefloquine does not eliminate
exoerythrocytic (hepatic phase) parasites. To avoid relapse,
after initial treatment of the acute infection with
mefloquine, patients should subsequently be treated with an
8-aminoquinoline (eg, primaquine).
In case of life-threatening,
serious or overwhelming malaria infections due to P.
falciparum, patients should be treated with an intravenous
antimalarial drug. Following completion of intravenous
treatment, mefloquine may be given to complete the course of
therapy.
Data on the use of
halofantrine subsequent to administration of mefloquine
suggest a significant, potentially fatal prolongation of the
QTc interval of the ECG. Therefore, halofantrine must not be
given simultaneously with or subsequent to mefloquine.
Mefloquine may cause
psychiatric symptoms in a number of patients, ranging from
anxiety, paranoia, and depression to hallucinations and
psychotic behavior. On occasions, these symptoms have been
reported to continue long after mefloquine has been stopped.
Rare cases of suicidal ideation and suicide have been
reported though no relationship to drug administration has
been confirmed. Mefloquine should be used with caution in
patients with a previous history of depression.
During prophylactic use, if
psychiatric symptoms such as acute anxiety, depression,
restlessness or confusion occur, these may be considered
prodromal to a more serious event. In these cases, the drug
must be discontinued and an alternative medication should be
substituted.
Concomitant administration of
mefloquine and quinine or quinidine may produce
electrocardiographic abnormalities. Concomitant
administration of mefloquine with quinine or chloroquine may
increase the risk of convulsions.
PRECAUTIONS:
General
Hypersensitivity reactions ranging from mild cutaneous
events to anaphylaxis cannot be predicted.
In patients with epilepsy, mefloquine may increase the risk
of convulsions. The drug should therefore be prescribed only
for curative treatment in such patients and only if there
are compelling medical reasons for its use.
Caution should be exercised
with regard to activities requiring alertness and fine
motor coordination such as driving, piloting aircraft,
operating machinery, and deep-sea diving, as dizziness, a
loss of balance, or other disorders of the central or
peripheral nervous system have been reported during and
following the use of mefloquine. These effects may occur
after therapy is discontinued due to the long half-life of
the drug. Mefloquine should be used with caution in patients
with psychiatric disturbances because mefloquine use has
been associated with emotional disturbances.
In patients with impaired
liver function the elimination of mefloquine may be
prolonged, leading to higher plasma levels.This drug has
been administered for longer than 1 year. If the drug is to
be administered for a prolonged period, periodic evaluations
including liver function tests should be performed.
Mefloquine should be used
with caution in patients with renal impairment.
Dosage :
Mexoquine should be taken
with plenty of water and preferably with food. The dosage
depends on the immune status and body weight of the patient.
Adults: 15-25 mg per kg body
weight or as per the physician’s advice.
Generic Manufacturer – Taj Pharmaceuticals
Our number one priority at Generic Manufacturing is to build
innovative and useful packaging, quality and manufacturing
drugs according to the customer's specifications. We can
customize one batch of Generic Medicine or an entire set of
products.
Taj
Pharmaceuticals Ltd. is a Pharmaceutical Generic manufacturer
of Mefloquine and manufacturer of various pharmaceutical
formulations in India. Taj Pharmaceuticals Ltd. provide
different pharmaceutical brands and Generic Medicines
The generic
manufacturing strategies of New Drug (Mefloquine) and the
product-process of Taj Pharmaceuticals Ltd. are compared and
collaborated using data from global Pharmaceuticals
manufacturing plants in the UK(Newcastle), US, Korea, Italy,
Germany and Japan.
We are an
eminent manufacturer, supplier and exporter of Mefloquine and
various pharmaceuticals generics medicines in Tablets,
capsules, Vial (injections), ampule, Strips and schedule packs
etc.
Mefloquine and
different pharma Tablet & Capsule formulations are also
available in different drug delivery forms. We also have large
volume manufacturing facilities for these Products.
With over two
decades of experience, we, Taj Pharmaceuticals Ltd., are one
of the leading generic pharmaceutical companies. We believe
that access to quality healthcare is a right, and not a
privilege. Therefore, we endeavor to ensure the availability
of world class, quality medicines at affordable prices across
the globe.
We are
committed to work towards a healthier and happier world. The
company is an integrated, research based international
pharmaceutical company, producing a wide range of quality,
affordable generic (Mefloquine) medicines, trusted by
health-care professionals and patients across geographies.
We offer you
the highest quality new Generic medicines ie. Mefloquine,
drugs and also with innovative packing at the lowest prices
shipped to you from India. Browse our latest Pharmaceuticals
and Generics possibilities and other pharmaceuticals
possibilities…more.
|
Quality
